Research and Markets : Femoro-Popliteal Angioplasty & Stenting is Your Exclusive Introduction to Top Companies and Their Forward-Thinking Technologies.DUBLIN, Ireland -- Peripheral Arterial Disease (PAD) of the Femoropopliteal System is a major cause of morbidity and limb loss accounting for over 300,000 amputations in the developed world every year. Medical therapy is often ineffective and open surgery has substantial risks. Less invasive endovascular approaches has been utilized for several decades in the Femoropopliteal System however, a major limiting factor A factor or condition that, either temporarily or permanently, impedes mission accomplishment. Illustrative examples are transportation network deficiencies, lack of in-place facilities, malpositioned forces or materiel, extreme climatic conditions, distance, transit or overflight rights, was late restenosis. Recent breakthroughs in stent material and design and the introduction of dedicated flexible stents with high radial force that can deliver superior outcome to open surgery promise to rewrite protocols of care and revolutionize the market for Lower Limb Endovascular Revascularization and Repair. Dublin - Research and Markets (http://www.researchandmarkets.com/reports/c21502) has announced the addition of Femoro-Popliteal Angioplasty angioplasty (ăn`jēōplăs'tē), any surgical repair of a blood vessel, especially balloon angioplasty or percutaneous transluminal coronary angioplasty, a treatment of coronary artery disease. & Stenting - Technology & Market Forecast to their offering "Femoro-Popliteal Angioplasty & Stenting - Technology & Market Forecast" report gives an overview of the state of both the technology and the market. It profiles the current market landscape and explores the market potential with global forecasts to 2010. The report draws on the latest findings presented at EuroPCR conference and details many pressing issues in the Fem-Pop Angioplasty & Stenting space including current approved and in-development devices and the status of clinical development of potential new entrants. Femoro-Popliteal Angioplasty & Stenting - Technology & Market Forecast is your exclusive introduction to top companies and their forward-thinking technologies. Report Highlights: - Current state of the science of superficial femoral artery femoral artery n. 1. An artery with origin at the continuation of the external iliac artery, with branches to the pudendal, epigastric, circumflex iliac arteries, the deep artery of the thigh, and the descending genicular artery, and (SFA See sales force automation. SFA - Sales Force Automation ) angioplasty & stenting. - Recent clinical trials and their findings. - Epidemiology of PAD, CLI (1) (Call Level Interface) A database programming interface from the SQL Access Group (SAG), an SQL membership organization. SAG's CLI is an attempt to standardize the SQL language for database access. and estimated number of endovascular procedures. - Current market for fem-pop angioplasty & stenting segmented geographically. - Potential market for fem-pop angioplasty, stenting, brachytherapy, laser therapy and plaque excision. - Leading players in the fem-pop angioplasty & stenting space and potential entrants. - Market forecasts to 2010. Femoro-Popliteal Angioplasty & Stenting - Technology & Market Forecast gives a short but thorough analysis of the global potential market for superficial femoral artery (SFA) endovascular repair. It is targeted at busy executives & venture capitalists Venture Capitalist An investor who provides capital to either start-up ventures or support small companies who wish to expand but do not have access to public funding. Notes: Venture capitalists usually expect higher returns for the additional risks taken. scanning for windows of opportunities opening in the peripheral endovascular space. Companies Mentioned inside this report: Boston Scientific The Boston Scientific Corporation (NYSE: BSX) (abbreviated BSC), is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a range of interventional medical specialties, including interventional cardiology, peripheral interventions, , Cook Group, C. R. Bard C. R. Bard, Inc. (NYSE: BCR) is one of the large S&P 500 companies of the United States, a surgical specialties and hospital medical device manufacturer in Murray Hill, New Jersey. It is named after its founder, who sold the company within only a few years of its founding. , Foxhollow Technologies, Johnson & Johnson, Cordis, Guidant, Other Companies in the Space, Abbott, AngioDynamics, B. Braun, CryoVascular Systems, Edwards Lifesciences Edwards Lifesciences (NYSE: EW) is a global leader in products and technologies to treat advanced cardiovascular disease, the global leader in acute hemodynamic monitoring and the number-one heart valve company in the world. , EV3, Gore Medical, IDev Technologies, Medtronic, Terumo and Vascular Architects For more information visit http://www.researchandmarkets.com/reports/c21502 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion